ReviewPharmacological research2017
Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
Review in Pharmacological research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.International journal of molecular sciences · 2021Trial
- PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction.Science advances · 2026Article
- Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response.Nature communications · 2023Article
- Orchestrated Action of AMPK Activation and Combined VEGF/PD-1 Blockade with Lipid Metabolic Tunning as Multi-Target Therapeutics against Ovarian Cancers.International journal of molecular sciences · 2022Review
- Article
- Nivolumab and ipilimumab immunotherapy for hemodialysis patients with advanced renal cell carcinoma.Current oncology (Toronto, Ont.) · 2020Article
- Immune-related adverse events of immune checkpoint inhibitors: a brief review.Current oncology (Toronto, Ont.) · 2018Review
- Phenotypic and genotypic heterogeneity of Lynch syndrome: a complex diagnostic challenge.Familial cancer · 2018Review
- Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.Journal for immunotherapy of cancer · 2018Article
- Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature.Oncotarget · 2018Article
- Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer.Scientific reports · 2018Article
- Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol.Scientific reports · 2018Article
- A Mechanistic Model for Predicting Cell Surface Presentation of Competing Peptides by MHC Class I Molecules.Frontiers in immunology · 2018Article
- Anti-PD-1 Therapy-Associated Perforating Colitis.Case reports in gastrointestinal medicine · 2018Article
- Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy.Current radiology reports · 2016Review
- Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The concept of augmenting the immune system to eradicate cancer dates back at least a century. A major resurgence in cancer immunotherapy has occurred over the past decade since the identification and targeting of negative regulators with antibody therapies to augment the anti-tumor immune response. Unprecedented responses across a broad array of cancer types elevated this class of therapies to the forefront of cancer treatment. The most successful drugs to date target the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) pathways. The immune biology of these pathways was illuminated through thoughtful pre-clinical experiments over the past 20 years. The characterization of these negative immune regulators, also known as immune checkpoints, subsequently led to the successful clinical development four drugs in six different cancer types to date, and progress continues. Despite these successes, significant challenges remain including the development of predictive biomarkers, recognition and management of immune related toxicities, and elucidating and reversing mechanisms of primary and secondary resistance. Ongoing work is expected to build upon recent accomplishments and allow more patients to benefit from this class of therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.